Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11655-020-3426-7 http://scihub22266oqcxt.onion/10.1007/s11655-020-3426-7 32676976!7364292!32676976     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Chin+J+Integr+Med 2020 ; 26 (9): 648-655 Nephropedia Template TP {{tp|p=32676976|t=2020. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial |pdf=|usr=}}{{32676976}} gab.com Text Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial JO: Chin J Integr Med http://www.kidney.de/pget.php?&tw=1&pmid=32676976 #FOAvip OBJECTIVES: To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. METHODS: A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 microg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group. After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed. RESULTS: An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048). CONCLUSIONS: Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No. NCT04251871 at www.clinicaltrials.gov ). Twit Text FOAVip Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial ????Chin J Integr Med http://www.kidney.de/pget.php?&tw=1&pmid=32676976 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32676976 #FOAvip English Wikipedia <ref>{{Cite pmid|32676976}}</ref> Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial #MMPMID32676976 Wang JB; Wang ZX; Jing J; Zhao P; Dong JH; Zhou YF; Yang G; Niu M; Zhao X; Jiang TJ; Bi JF; Xu Z; Zhang P; Wu D; Bai ZF; Guo YM; Yu SM; Sun YQ; Zhang ZT; Zhan XY; Li PY; Ding JB; Zhao PF; Song XA; Tang JY; He DC; Chen Z; Qin EQ; Wang RL; Xiao XH Chin J Integr Med 2020[Sep]; 26 (9): 648-655 PMID32676976show ga OBJECTIVES: To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. METHODS: A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 microg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group. After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed. RESULTS: An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048). CONCLUSIONS: Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No. NCT04251871 at www.clinicaltrials.gov ). |Administration, Inhalation[MESH] |Adult[MESH] |COVID-19[MESH] |China[MESH] |Coronavirus Infections/diagnosis/*drug therapy/mortality[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Administration Schedule[MESH] |Drugs, Chinese Herbal/*administration & dosage[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Integrative Medicine[MESH] |Interferon-alpha/*administration & dosage[MESH] |Lopinavir/*administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/mortality[MESH] |Risk Assessment[MESH] |Severe Acute Respiratory Syndrome/diagnosis/*drug therapy/mortality[MESH] |Severity of Illness Index[MESH]Exploring an Integrative Therapy for Treating COVID-19: A Randomized C(epmc).pdf DeepDyve Pubget Overpricing